Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
IMMUNOACTimmunoact.com · Low evidenceImmunoACT develops and manufactures CAR T cell therapies, including India's first approved CAR T therapy NexCAR19, which genetically modifies a patient's immune cells to fight cancer. The company partners with Cipla to commercialize Talicabtagene autoleucel in Africa, expanding access to advanced cancer care in South Africa, Algeria, and Morocco.
Parse Score